Maxime Ranger

Maxime Ranger is a highly experienced executive in the biotech and pharmaceutical industries, currently serving as Chief Executive Officer of Neurenati, where efforts focus on treating Hirschsprung disease. As Cofounder and CEO of Numbio Therapeutics, Maxime directs a startup addressing tau-related neuropathies in ophthalmology. Additionally, Maxime holds advisory roles at Néolys Pharma, OBaris, and Matrix Innovation Inc., contributing expertise in drug delivery and anti-infectious drug development. Maxime also consults for various VC funds as an asset valuation expert at Gestion MRIM Inc. Academic engagement includes being an Adjunct Professor at Université de Montréal and previous leadership as CEO and Executive Chairman of giiant pharma inc. Notably, Maxime plays a significant role in the cultural sector as Président du conseil d’administration at Théâtre Denise-Pelletier and has co-founded Sweet Pharma Day, fostering collaboration in the pharmaceutical community. Educational credentials include advanced degrees from renowned institutions, emphasizing expertise in materials sciences, pharmaceutical technology, and business administration.